Clinical data | |
---|---|
Trade names | Vexol |
Other names | Trimexolone; Org 6216; 11β-Hydroxy-16α,17α,21-trimethylpregna-1,4-dien-3,20-dione |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606003 |
Routes of administration | Eye drops |
ATC code | |
Pharmacokinetic data | |
Elimination half-life | estimated 1–2 hours |
Excretion | >80% faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.211.227 |
Chemical and physical data | |
Formula | C24H34O3 |
Molar mass | 370.533 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye.[1] It is marketed as a 1% eye drop suspension under the trade name Vexol by Alcon Laboratories, but was discontinued in the US and other countries.[2][3]